Sejong Medical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Sejong Medical makes single-use surgical instruments, such as trocars (the hollow tubes that allow tools to enter the body), specimen retrieval bags, and suction-irrigation electrodes, used in laparoscopic (keyhole) surgery, which causes less pain and scarring than open surgery.
Its products are supplied to hospitals and distributors, and because the instruments are disposable and cannot be reused, demand tracks the number of laparoscopic procedures performed. Listed on KOSDAQ, Korea's tech and small-cap board, the company handles the entire production process in-house, from design and mold-making through assembly and sterilization, and exports to dozens of countries worldwide.
Summary is AI-generated and may contain errors · figures from DART filings
The company holds over eighty intellectual-property registrations related to laparoscopic surgery and carries international quality certifications including European CE and Japanese JFDA approvals.
Sejong Medical in five facts
What does Sejong Medical do?
Sejong Medical makes single-use surgical instruments, such as trocars (the hollow tubes that allow tools to enter the body), specimen retrieval bags, and suction-irrigation electrodes, used in laparoscopic (keyhole) surgery, which causes less pain and scarring than open surgery.
Where is Sejong Medical listed and in which sector?
Sejong Medical (Korean name: 세종메디칼) trades under KRX code 258830 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Sejong Medical?
Its market capitalisation was US$23.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Sejong Medical's latest annual revenue and operating profit?
For fiscal year 2025, Sejong Medical reported revenue of US$14M, operating profit of US$1.7M and a net loss of US$19.2K, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 2.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 8
- [Amended] Half-year report (2026.06)Oct 8
- DisclosureOct 7
- [Amended] Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 1
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Sejong Medical reported consolidated results for FY2025: revenue of US$12.9M (−2.2% year on year), operating profit of US$1.58M (from a loss a year earlier) and a net loss of US$3.43M.
Earnings · Feb 25